• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

    8/29/25 8:05:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EBS alert in real time by email
    • Pro Football Hall of Famer and Ready to Rescue campaign spokesperson, Emmitt Smith, and Release Recovery Founder/CEO, Zac Clark, plan to visit several U.S. college campuses to educate on opioid emergency preparedness
    • New sponsorship of Mobilize Recovery's "Campus Surge" initiative brings addiction prevention and recovery support to higher education institutions

    GAITHERSBURG, Md., Aug. 29, 2025 (GLOBE NEWSWIRE) -- In honor of International Overdose Awareness Day (IOAD) on August 31, Emergent BioSolutions (NYSE:EBS) is re-launching its Ready to Rescue public education campaign, which raises awareness of opioid emergencies and the importance of being prepared with NARCAN® Nasal Spray among young adults at college/university activations with Greek Life, wellness services and athletic departments. Together, Pro Football Hall of Famer and campaign spokesperson, Emmitt Smith, and Release Recovery founder and CEO, Zac Clark will lead inspiring conversations to break down the stigma around accidental opioid poisonings and empower students to be ready to save a life with over-the-counter NARCAN® Nasal Spray.

    Despite encouraging data showing a decline in overdose deaths in 2024,i the dangers of the opioid crisis remain ever present. A recent report from Mental Health America analyzing publicly available national data shows that progress in reducing overdose deaths is not uniform across the country, with some states differing significantly on prevention strategies and overdose reduction. The report provides a comprehensive ranking of opioid overdose responses across every state, analyzing four systems that have the greatest potential for impact including public health, healthcare, schools and jails.

    The new report identifies Texas, Illinois, Louisiana and Michigan as states in need of the most opioid overdose response support in at least one system. This fall, Ready to Rescue will host a tailgate activation at schools near Chicago, IL, and will be joined by Release U – Release Recovery's digital personal development and mental wellness platform designed to meet the needs of today's students in Dallas, TX, Baton Rouge, LA and Detroit/Ann Arbor, MI. In light of the rise of synthetic opioids, like fentanyl, paired with potential stressors that many students face,ii Smith and Clark will discuss the connection between mental health and substance use, while encouraging students to look out for each other by normalizing these topics. During the events, attendees will also receive Ready to Rescue kits with information on the signs of an opioid emergency and watch NARCAN® Nasal Spray demonstrations, so they can be prepared to save a life using the simple "Lay, Spray, Stay" method.

    "Having personally navigated the profound challenges of opioid dependency after brain surgery and supported so many truly incredible people on their sobriety journeys at Release Recovery, I know that opioid emergencies can happen to anyone, anywhere, at any time," said Zac Clark, founder & CEO of Release Recovery. "I'm proud to be teaming up with Emergent for these campus events to extend critical naloxone resources that will help the next generation be better prepared in an opioid emergency. Every conversation is an important step in changing the course of the epidemic, and ultimately, saving lives."

    Opioid misuse and dependency is the highest among young adults ages 18 to 25,iii yet less than 15 percent of American college students know how to administer live-saving opioid reversal naloxone medications.iv In honor of IOAD's focus on overdose prevention and to help close this gap, Emergent is also sponsoring Mobilize Recovery's Campus Surge initiative, which will provide action-driven overdose education and harm reduction engagement across several additional college campuses nationwide. This year, Campus Surge will provide life-saving resources and prevention tools to schools at the start of the academic year to empower students to activate change.

    "On International Overdose Awareness Day and every day, Emergent honors the countless lives lost from opioid overdoses, and is committed to leading and strengthening our efforts across the U.S. and Canada to help reduce the devastating toll of this public health crisis," said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. "Our mission is to protect and save lives – and that is fulfilled when we positively impact at-risk and vulnerable communities, like college students, while also ensuring widespread access and awareness of over-the-counter NARCAN® Nasal Spray 4 mg, so more people can be ready to rescue when it matters most."

    Recognizing the signs of an opioid overdose/poisoning—such as trouble breathing, pinpoint pupils, and pale and clammy skin—and acting quickly can be the difference between successfully reversing the effects of a poisoning, and not.v Visit ReadytoRescue.com for additional education and resources, and to learn how to be prepared in an opioid overdose emergency with life-saving intranasal naloxone visit NARCAN.com (U.S. site) and NARCANNasalSpray.ca (Canada site).

    Emmitt Smith and Zac Clark are paid spokespeople for Emergent.

    About NARCAN® Nasal Spray

    NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.

    About Emergent BioSolutions

    At Emergent, our mission is to protect and save lives. For over 25 years, we've been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today's health challenges and tomorrow's threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

    Investor Contact:

    Richard S. Lindahl

    Executive Vice President, CFO

    [email protected]

    Media Contact:

    Assal Hellmer

    Vice President, Communications

    [email protected]

    _____________________________

    i https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2025/20250514.htm

    ii https://americanaddictioncenters.org/rehab-guide/college

    iii https://pmc.ncbi.nlm.nih.gov/articles/PMC8750763/

    iv https://pubmed.ncbi.nlm.nih.gov/38648053/

    v Product Monograph. 2025. NARCAN® Nasal Spray. Retrieved from https://narcannasalspray.ca/PM/NNS_EN.pdf.



    Primary Logo

    Get the next $EBS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EBS

    DatePrice TargetRatingAnalyst
    12/30/2024$15.00Buy
    H.C. Wainwright
    8/22/2024$16.00Buy
    Rodman & Renshaw
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    11/20/2023Underweight
    JP Morgan
    8/29/2023Buy → Hold
    The Benchmark Company
    4/10/2023$22.00Hold → Buy
    The Benchmark Company
    3/17/2023$23.00 → $9.00Neutral → Underweight
    JP Morgan
    11/10/2022Buy → Hold
    The Benchmark Company
    More analyst ratings

    $EBS
    SEC Filings

    View All

    Emergent BioSolutions Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

    9/5/25 5:23:20 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Emergent BioSolutions Inc.

    EFFECT - Emergent BioSolutions Inc. (0001367644) (Filer)

    8/18/25 12:15:25 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Emergent BioSolutions Inc.

    144 - Emergent BioSolutions Inc. (0001367644) (Subject)

    8/15/25 4:04:54 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Papa Joseph C bought $349,800 worth of shares (60,000 units at $5.83), increasing direct ownership by 21% to 342,500 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    5/15/25 4:02:40 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

    GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales for ACAM2000® vaccine and ancillary products to more than $120 million this year from a diverse base of customers. ACAM2000® is licensed for active immunization against smallpox and mpox disease for persons determined to be at high risk for smallpox or mpox infection. "Our new contract modification for ACAM2000® vaccine reflects the conti

    9/9/25 7:30:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

    GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to begin this calendar year and are scheduled to be completed by March 2026. "This new contract modification is the next step in our ongoing engagement with the U.S. government, with the shared goal to help ensure medical countermeasures, like

    9/2/25 7:40:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

    Pro Football Hall of Famer and Ready to Rescue campaign spokesperson, Emmitt Smith, and Release Recovery Founder/CEO, Zac Clark, plan to visit several U.S. college campuses to educate on opioid emergency preparednessNew sponsorship of Mobilize Recovery's "Campus Surge" initiative brings addiction prevention and recovery support to higher education institutions GAITHERSBURG, Md., Aug. 29, 2025 (GLOBE NEWSWIRE) -- In honor of International Overdose Awareness Day (IOAD) on August 31, Emergent BioSolutions (NYSE:EBS) is re-launching its Ready to Rescue public education campaign, which raises awareness of opioid emergencies and the importance of being prepared with NARCAN® Nasal Spray among

    8/29/25 8:05:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

    H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

    12/30/24 7:24:57 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Emergent BioSolutions with a new price target

    Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00

    8/22/24 7:22:39 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00

    3/7/24 10:14:18 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zoon Kathryn C sold $62,853 worth of shares (7,086 units at $8.87), decreasing direct ownership by 9% to 71,799 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    8/18/25 4:33:31 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Degolyer Donald W sold $67,831 worth of shares (7,844 units at $8.65), decreasing direct ownership by 5% to 137,659 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    8/13/25 4:22:58 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Bioservices Hartzel William covered exercise/tax liability with 4,263 shares, decreasing direct ownership by 4% to 103,692 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    7/15/25 4:04:10 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Leadership Updates

    Live Leadership Updates

    View All

    Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

    Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an

    11/4/24 7:30:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

    Ongoing support of the ‘White House Challenge to Save Lives from Overdose' through workplace and public safety measuresOne-year mark of Ready to Rescue public awareness campaign to expand awareness, particularly among young adults and vulnerable communities20,000 additional doses of NARCAN® Nasal Spray to be donated to organizations in need GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emerg

    10/8/24 5:32:28 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

    MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

    9/4/24 8:00:00 AM ET
    $CADL
    $EBS
    $MIST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $EBS
    Financials

    Live finance-specific insights

    View All

    Emergent BioSolutions Reports Second Quarter 2025 Financial Results

    Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 millionSecond Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, versus prior yearSecond Quarter 2025 Gross Margin % of 36% and Adjusted Gross Margin % of 49%, an expansion of 6,200 bps and 2,300 bps, respectively, versus prior yearSecond Quarter 2025 Adjusted EBITDA of $28.5 million, an increase of 382% versus prior yearSecond Quarter 2025 Adjusted EBITDA Margin of 20% of Total Revenues, an improvement of 2,400 bps versus prior yearRaising the low end/midpoint of Full Year 2025 Profitability Guidance GAITHERSBURG, Md., Aug. 06, 2025 (GLOBE NE

    8/6/25 4:15:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

    GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be

    7/15/25 7:30:16 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Reports First Quarter 2025 Financial Results

    First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior yearReaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 

    5/7/25 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Emergent BioSolutions Inc.

    SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/13/24 4:00:18 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/8/24 5:23:28 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    9/10/24 12:09:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care